Targeting RAF kinases for cancer therapy: BRAF-mutate

Nature Reviews Cancer

14, 455-467

DOI: 10.1038/nrc3760

Citation Report

#	Article	IF	Citations
1	BRAF mutation in hairy cell leukemia. Oncology Reviews, 2014, 8, 253.	0.8	12
2	Dimerization-induced allostery in protein kinase regulation. Trends in Biochemical Sciences, 2014, 39, 475-486.	3.7	80
3	NCCN Working Group Report: Designing Clinical Trials in the Era of Multiple Biomarkers and Targeted Therapies. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1629-1649.	2.3	18
4	Understanding melanoma stem cells. Melanoma Management, 2015, 2, 179-188.	0.1	29
5	Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort. Journal of Thoracic Oncology, 2015, 10, 1451-1457.	0.5	141
6	DARPA's Big Mechanism program. Physical Biology, 2015, 12, 045008.	0.8	48
7	Research Resource: Androgen Receptor Activity Is Regulated Through the Mobilization of Cell Surface Receptor Networks. Molecular Endocrinology, 2015, 29, 1195-1218.	3.7	8
8	BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity. Blood, 2015, 125, 1207-1216.	0.6	82
9	AM251 induces apoptosis and G2/M cell cycle arrest in A375 human melanoma cells. Anti-Cancer Drugs, 2015, 26, 754-762.	0.7	22
10	Comparative Aspects of BRAF Mutations in Canine Cancers. Veterinary Sciences, 2015, 2, 231-245.	0.6	25
11	Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR. Pharmacogenomics and Personalized Medicine, 2015, 8, 63.	0.4	24
12	Anatomy of protein disorder, flexibility and disease-related mutations. Frontiers in Molecular Biosciences, 2015, 2, 47.	1.6	16
13	Biophysical Characterization of Essential Phosphorylation at the Flexible C-Terminal Region of C-Raf with 14-3-3Î¶ Protein. PLoS ONE, 2015, 10, e0135976.	1.1	9
14	Detection of BRAF Mutation in Urine DNA as a Molecular Diagnostic for Canine Urothelial and Prostatic Carcinoma. PLoS ONE, 2015, 10, e0144170.	1.1	84
15	Alike but Different: RAF Paralogs and Their Signaling Outputs. Cell, 2015, 161, 967-970.	13.5	90
16	Activation of the Mitochondrial Fragmentation Protein DRP1 Correlates with BRAF V600E Melanoma. Journal of Investigative Dermatology, 2015, 135, 2544-2547.	0.3	48
17	Low inducible expression of p21Cip1 confers resistance to paclitaxel in BRAF mutant melanoma cells with acquired resistance to BRAF inhibitor. Molecular and Cellular Biochemistry, 2015, 406, 53-62.	1.4	3
18	Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet?. Expert Review of Molecular Diagnostics, 2015, 15, 1631-1644.	1.5	53

#	Article	IF	Citations
19	Next-generation sequencing reveals rare genomic alterations in aggressive digital papillary adenocarcinoma. Annals of Diagnostic Pathology, 2015, 19, 381-384.	0.6	24
20	BRAF Alterations as Therapeutic Targets in Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 1396-1403.	0.5	76
21	Progress in targeting RAF kinases for cancer therapy. Personalized Medicine, 2015, 12, 183-186.	0.8	1
22	Circulating Biomarkers in Malignant Melanoma. Advances in Clinical Chemistry, 2015, 69, 47-89.	1.8	34
23	Personalized treatment for colorectal cancer: novel developments and putative therapeutic strategies. Langenbeck's Archives of Surgery, 2015, 400, 129-143.	0.8	14
24	ZEB1: At the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance. Cell Cycle, 2015, 14, 481-487.	1.3	482
25	Novel Targets for the Treatment of Ameloblastoma. Journal of Dental Research, 2015, 94, 237-240.	2.5	57
26	Patient-specific driver gene prediction and risk assessment through integrated network analysis of cancer omics profiles. Nucleic Acids Research, 2015, 43, e44-e44.	6.5	111
27	The difference between medicine and magic is that magicians know what they are doing. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1-4.	3.3	25
28	FBXW7 modulates cellular stress response and metastatic potential through HSF1 post-translational modification. Nature Cell Biology, 2015, 17, 322-332.	4.6	134
29	Dendritic Cell Disorders: Matters of Lineage and Clinical Drug Testing in Rare Diseases. Journal of Clinical Oncology, 2015, 33, 383-385.	0.8	5
30	Oncogene-directed small molecule inhibitors for the treatment of cutaneous melanoma. Melanoma Management, 2015, 2, 133-147.	0.1	3
31	Synthetic approaches to protein phosphorylation. Current Opinion in Chemical Biology, 2015, 28, 115-122.	2.8	93
33	Comprehensive genomic profiles of small cell lung cancer. Nature, 2015, 524, 47-53.	13.7	1,634
34	Targeting cancer with kinase inhibitors. Journal of Clinical Investigation, 2015, 125, 1780-1789.	3.9	364
35	The Effect of a Widespread Cancer-Causing Mutation on the Inactive to Active Dynamics of the B-Raf Kinase. Journal of the American Chemical Society, 2015, 137, 5280-5283.	6.6	37
36	Melanoma Treatments: Advances and Mechanisms. Journal of Cellular Physiology, 2015, 230, 2626-2633.	2.0	40
37	Melanoma cells with acquired resistance to dabrafenib display changes in miRNA expression pattern and respond to this drug with an increase of invasiveness, which is abrogated by inhibition of NF-Î²B or the PI3K/mTOR signalling pathway. Journal of Translational Medicine, 2015, 13, P5.	1.8	0

#	Article	IF	Citations
38	N-(3-Ethynyl-2,4-difluorophenyl)sulfonamide Derivatives as Selective Raf Inhibitors. ACS Medicinal Chemistry Letters, 2015, 6, 543-547.	1.3	32
39	Quinazoline derivatives as anticancer drugs: a patent review (2011 â€“ present). Expert Opinion on Therapeutic Patents, 2015, 25, 789-804.	2.4	93
40	KRAS as a Therapeutic Target. Clinical Cancer Research, 2015, 21, 1797-1801.	3.2	262
41	RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?. Clinical Cancer Research, 2015, 21, 1802-1809.	3.2	146
42	Lin28B promotes melanoma growth by mediating a microRNA regulatory circuit. Carcinogenesis, 2015, 36, 937-945.	1.3	19
43	MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nature Reviews Cancer, 2015, 15, 577-592.	12.8	461
44	Drug Resistance Resulting from Kinase Dimerization Is Rationalized by Thermodynamic Factors Describing Allosteric Inhibitor Effects. Cell Reports, 2015, 12, 1939-1949.	2.9	37
45	Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes. Cancer Cell, 2015, 28, 170-182.	7.7	120
46	The role of the transcription factor Ets1 in carcinoma. Seminars in Cancer Biology, 2015, 35, 20-38.	4.3	174
47	Limited Proteolysis Combined with Stable Isotope Labeling Reveals Conformational Changes in Protein (Pseudo)kinases upon Binding Small Molecules. Journal of Proteome Research, 2015, 14, 4179-4193.	1.8	7
48	Protein Modifications in Pathogenic Dysregulation of Signaling. , 2015, , .		0
49	Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells. Cancer Research, 2015, 75, 5355-5366.	0.4	33
50	A-Raf: A new star of the family of raf kinases. Critical Reviews in Biochemistry and Molecular Biology, 2015, 50, 520-531.	2.3	31
51	PI3â€²-Kinase Inhibition Forestalls the Onset of MEK1/2 Inhibitor Resistance in BRAF-Mutated Melanoma. Cancer Discovery, 2015, 5, 143-153.	7.7	51
52	Beyond BRAF: where next for melanoma therapy?. British Journal of Cancer, 2015, 112, 217-226.	2.9	99
53	Initial response of renal cell carcinoma to vemurafenib in a patient treated for metastatic melanoma. Canadian Urological Association Journal, 2016, 10, 306.	0.3	0
54	Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles. Oncotarget, 2016, 7, 26628-26652.	0.8	25
55	Nanodelivery of Anticancer Agents in Melanoma. , 2016, , 189-201.		2

#	Article	IF	Citations
56	The yinâ€“yang of kinase activation and unfolding explains the peculiarity of Val600 in the activation segment of BRAF. ELife, 2016, 5, e12814.	2.8	34
57	The Quest for Targets Executing MYC-Dependent Cell Transformation. Frontiers in Oncology, 2016, 6, 132.	1.3	30
58	Adapt, Recycle, and Move on: Proteostasis and Trafficking Mechanisms in Melanoma. Frontiers in Oncology, 2016, 6, 240.	1.3	25
59	HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B. PLoS Computational Biology, 2016, 12, e1004827.	1.5	27
60	Melanoma Expressed-CD70 Is Regulated by RhoA and MAPK Pathways without Affecting Vemurafenib Treatment Activity. PLoS ONE, 2016, 11, e0148095.	1.1	7
61	Comparison of the Lonidamine Potentiated Effect of Nitrogen Mustard Alkylating Agents on the Systemic Treatment of DB-1 Human Melanoma Xenografts in Mice. PLoS ONE, 2016, 11, e0157125.	1.1	8
62	Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view. Chemical Society Reviews, 2016, 45, 4929-4952.	18.7	150
63	TGFÎ² induces epithelialâ€mesenchymal transition of thyroid cancer cells by both the BRAF/MEK/ERK and Src/FAK pathways. Molecular Carcinogenesis, 2016, 55, 1639-1654.	1.3	30
64	Inhibitors of Rasâ€“SOS Interactions. ChemMedChem, 2016, 11, 814-821.	1.6	62
65	Integrated genomic and functional analyses of histone demethylases identify oncogenic KDM2A isoform in breast cancer. Molecular Carcinogenesis, 2016, 55, 977-990.	1.3	40
66	MEK inhibitor treatment is effective in a patient with metastatic carcinoma of the ampulla of Vater with BRAF and NRAS mutations shown by next-generation sequencing. Anti-Cancer Drugs, 2016, 27, 569-572.	0.7	2
67	Pin1â€“FOXM1 inhibitors: a potential therapeutic for metastatic melanoma?. Melanoma Management, 2016, 3, 161-164.	0.1	2
68	Personalized Treatment for a Patient With aBRAFV600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From Ganglioglioma. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1345-1350.	2.3	23
69	Hotspot mutations delineating diverse mutational signatures and biological utilities across cancer types. BMC Genomics, 2016, 17, 394.	1.2	28
70	Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor. International Journal of Oncology, 2016, 49, 1164-1174.	1.4	52
71	<scp>ZEB</scp> 1â€mediated melanoma cell plasticity enhances resistance to <scp>MAPK</scp> inhibitors. EMBO Molecular Medicine, 2016, 8, 1143-1161.	3.3	98
72	Optogenetically controlled RAF to characterize BRAF and CRAF protein kinase inhibitors. Scientific Reports, 2016, 6, 23713.	1.6	19
73	Activation loop phosphorylation regulates Bâ€Raf inÂvivo and transformation by <scp>Bâ€Raf</scp> mutants. EMBO Journal, 2016, 35, 143-161.	3.5	29

#	Article	IF	Citations
74	RIG-like Helicase Regulation of Chitinase 3-like 1 Axis and Pulmonary Metastasis. Scientific Reports, 2016, 6, 26299.	1.6	21
75	Design and synthesis of N -(4-aminopyridin-2-yl)amides as B-Raf V600E inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2760-2763.	1.0	7
76	Whole exome sequencing identifies lncRNAGAS8-AS1andLPAR4as novel papillary thyroid carcinoma driver alternations. Human Molecular Genetics, 2016, 25, 1875-1884.	1.4	79
77	Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAF^{V600E} melanoma. OncoImmunology, 2016, 5, e1089381.	2.1	32
78	Role of the protein kinase BRAF in the pathogenesis of endometriosis. Expert Opinion on Therapeutic Targets, 2016, 20, 1017-1029.	1.5	9
79	The metabolic microenvironment of melanomas: Prognostic value of MCT1 and MCT4. Cell Cycle, 2016, 15, 1462-1470.	1.3	66
80	Transketolase-like 1 ectopic expression is associated with DNA hypomethylation and induces the Warburg effect in melanoma cells. BMC Cancer, 2016, 16, 134.	1.1	27
81	Design, synthesis and biological evaluation of novel benzo-Î±-pyrone containing piperazine derivatives as potential BRAF V600E inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4983-4991.	1.0	7
82	Macrocyclic Lactones Block Melanoma Growth, Metastases Development and Potentiate Activity of Antiâ€“BRAF V600 Inhibitors. Clinical Skin Cancer, 2016, 1, 4-14.e3.	0.1	8
83	Molecular signaling cascades involved in nonmelanoma skin carcinogenesis. Biochemical Journal, 2016, 473, 2973-2994.	1.7	37
84	The value of genomics in dissecting the RAS-network and in guiding therapeutics for RAS-driven cancers. Seminars in Cell and Developmental Biology, 2016, 58, 108-117.	2.3	10
85	Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma. Nature Medicine, 2016, 22, 1056-1061.	15.2	62
86	A novel somatic MAPK1 mutation in primary ovarian mixed germ cell tumors. Oncology Reports, 2016, 35, 725-730.	1.2	8
87	The distribution of <scp>BRAF</scp> gene fusions in solid tumors and response to targeted therapy. International Journal of Cancer, 2016, 138, 881-890.	2.3	248
88	Keratoacanthoma: a distinct entity?. Experimental Dermatology, 2016, 25, 85-91.	1.4	30
89	Panax notoginseng saponins attenuate lung cancer growth in part through modulating the level of Met/miR-222 axis. Journal of Ethnopharmacology, 2016, 193, 255-265.	2.0	44
90	MAPK kinase signalling dynamics regulate cell fate decisions and drug resistance. Current Opinion in Structural Biology, 2016, 41, 151-158.	2.6	72
91	Molecular Pathways: Maintaining MAPK Inhibitor Sensitivity by Targeting Nonmutational Tolerance. Clinical Cancer Research, 2016, 22, 5966-5970.	3.2	41

#	Article	IF	Citations
92	Activity-Based Protein Profiling Shows Heterogeneous Signaling Adaptations to BRAF Inhibition. Journal of Proteome Research, 2016, 15, 4476-4489.	1.8	16
94	Inhibition of Ral GTPases Using a Stapled Peptide Approach. Journal of Biological Chemistry, 2016, 291, 18310-18325.	1.6	20
95	Autophosphorylation on S614 inhibits the activity and the transforming potential of BRAF. Cellular Signalling, 2016, 28, 1432-1439.	1.7	6
96	Paradoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cells. Scientific Reports, 2016, 6, 26803.	1.6	14
97	Emerging Role of Genomic Rearrangements in Breast Cancer: Applying Knowledge from Other Cancers. Biomarkers in Cancer, 2016, 8s1, BIC.S34417.	3.6	27
98	BRAF and NRAS mutations in Russian melanoma patients: results of a nationwide study. Melanoma Research, 2016, 26, 442-447.	0.6	5
99	Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF V600 Mutation. Targeted Oncology, 2016, 11, 417-428.	1.7	37
100	The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas. Molecular Cancer Therapeutics, 2016, 15, 1859-1869.	1.9	16
101	Generation and analysis of zebrafish melanoma models. Methods in Cell Biology, 2016, 134, 531-549.	0.5	13
102	Making sense of big data in health research: Towards an EU action plan. Genome Medicine, 2016, 8, 71.	3.6	190
103	Is the Canonical RAF/MEK/ERK Signaling Pathway aÂTherapeutic Target in SCLC?. Journal of Thoracic Oncology, 2016, 11, 1233-1241.	0.5	44
104	A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib. EBioMedicine, 2016, 8, 132-149.	2.7	44
105	Emerging Role of mTOR in the Response to Cancer Therapeutics. Trends in Cancer, 2016, 2, 241-251.	3.8	95
106	ERK mediated upregulation of death receptor 5 overcomes the lack of p53 functionality in the diaminothiazole DAT1 induced apoptosis in colon cancer models: efficiency of DAT1 in Ras-Raf mutated cells. Molecular Cancer, 2016, 15, 22.	7.9	7
107	The complexities and versatility of the RAS-to-ERK signalling system in normal and cancer cells. Seminars in Cell and Developmental Biology, 2016, 58, 96-107.	2.3	51
108	Anticancer metal drugs and immunogenic cell death. Journal of Inorganic Biochemistry, 2016, 165, 71-79.	1.5	107
109	Ras Conformational Ensembles, Allostery, and Signaling. Chemical Reviews, 2016, 116, 6607-6665.	23.0	290
110	Epithelialâ€“mesenchymal transition: a new target in anticancer drug discovery. Nature Reviews Drug Discovery, 2016, 15, 311-325.	21.5	290

#	Article	IF	Citations
111	PutativeBRAFactivating fusion in a medullary thyroid cancer. Journal of Physical Education and Sports Management, 2016, 2, a000729.	0.5	14
112	Cobimetinib and vemurafenib for the treatment of melanoma. Expert Opinion on Pharmacotherapy, 2016, 17, 1005-1011.	0.9	21
113	Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives. Journal of the National Cancer Institute, 2016, 108, djv414.	3.0	81
114	Novobiocin Analogues That Inhibit the MAPK Pathway. Journal of Medicinal Chemistry, 2016, 59, 925-933.	2.9	11
115	BMI1 induces an invasive signature in melanoma that promotes metastasis and chemoresistance. Genes and Development, 2016, 30, 18-33.	2.7	53
116	Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120. Cancer Discovery, 2016, 6, 300-315.	7.7	134
117	Novel Treatments in Development for Melanoma. Cancer Treatment and Research, 2016, 167, 371-416.	0.2	15
118	Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. Journal of the National Cancer Institute, 2016, 108, djv310.	3.0	182
119	Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy. Oncogene, 2016, 35, 2547-2561.	2.6	75
120	Discrete cytosolic macromolecular <scp>BRAF</scp> complexes exhibit distinct activities and composition. EMBO Journal, 2017, 36, 646-663.	3.5	52
121	The current state of clinical interpretation of sequence variants. Current Opinion in Genetics and Development, 2017, 42, 33-39.	1.5	77
122	A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas. Neuro-Oncology, 2017, 19, now261.	0.6	55
123	Lymph Node Metastasisâˆ—âˆ—Funded in part by the Nathanson/Rands Chair in Breast Cancer Research. Artwork by Kelly Rosso, MD, and Dhananjay Chitale, MD.. , 2017, , 235-261.		5
124	BRAF inhibitor-associated cutaneous squamous cell carcinoma: new mechanistic insight, emerging evidence for viral involvement and perspectives on clinical management. British Journal of Dermatology, 2017, 177, 914-923.	1.4	29
125	Mechanisms of Drug Resistance in Melanoma. Handbook of Experimental Pharmacology, 2017, 249, 91-108.	0.9	63
126	Beyond the BRAF ^V ^{600E} hotspot: biology and clinical implications of rare BRAF gene mutations in melanoma patients. British Journal of Dermatology, 2017, 177, 936-944.	1.4	39
127	PIK3CAâ€mutated melanoma cells rely on cooperative signaling through mTORC1/2 for sustained proliferation. Pigment Cell and Melanoma Research, 2017, 30, 353-367.	1.5	9
128	The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function. Cancer Discovery, 2017, 7, 424-441.	7.7	57

#	Article	IF	Citations
129	ACY-1215 accelerates vemurafenib induced cell death of BRAF-mutant melanoma cells via induction of ER stress and inhibition of ERK activation. Oncology Reports, 2017, 37, 1270-1276.	1.2	27
130	In vitro long-term treatment with MAPK inhibitors induces melanoma cells with resistance plasticity to inhibitors while retaining sensitivity to CD8 T cells. Oncology Reports, 2017, 37, 1367-1378.	1.2	5
131	Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice. Cancer Research, 2017, 77, 1250-1260.	0.4	68
132	Identification of novel B-RafV600E inhibitors employing FBDD strategy. Biochemical Pharmacology, 2017, 132, 63-76.	2.0	17
133	Time-resolved Phosphoproteome Analysis of Paradoxical RAF Activation Reveals Novel Targets of ERK. Molecular and Cellular Proteomics, 2017, 16, 663-679.	2.5	26
134	Targeting BMK1 Impairs the Drug Resistance to Combined Inhibition of BRAF and MEK1/2 in Melanoma. Scientific Reports, 2017, 7, 46244.	1.6	19
135	New Challenges in Cancer Therapy: MAPK Inhibitors from Bench to Bedside. , 2017, , 67-91.		1
136	BRaf signaling principles unveiled by large-scale human mutation analysis with a rapid lentivirus-based gene replacement method. Genes and Development, 2017, 31, 537-552.	2.7	20
137	Genetics of common complex diseases: a view from Iceland. European Journal of Internal Medicine, 2017, 41, 3-9.	1.0	3
138	ETSâ€targeted therapy: can it substitute for MEK inhibitors?. Clinical and Translational Medicine, 2017, 6, 16.	1.7	30
139	The landscape of BRAF transcript and protein variants in human cancer. Molecular Cancer, 2017, 16, 85.	7.9	22
140	MYC and RAF: Key Effectors in Cellular Signaling and Major Drivers in Human Cancer. Current Topics in Microbiology and Immunology, 2017, 407, 117-151.	0.7	25
141	Oncogenic RAS Regulates Long Noncoding RNA Orilnc1 in Human Cancer. Cancer Research, 2017, 77, 3745-3757.	0.4	34
142	Mucosal melanoma of the upper airways tract mucosal melanoma: A systematic review with meta-analyses of treatment. Head and Neck, 2017, 39, 819-825.	0.9	35
143	Molecular Genetics of Endometrial Carcinoma. Advances in Experimental Medicine and Biology, 2017, , .	0.8	6
144	Endometrial Carcinoma: Specific Targeted Pathways. Advances in Experimental Medicine and Biology, 2017, 943, 149-207.	0.8	53
145	Targeted Disruption of V600E-Mutant BRAF Gene by CRISPR-Cpf1. Molecular Therapy - Nucleic Acids, 2017, 8, 450-458.	2.3	27
146	BRAF Mutation is Associated with an Improved Survival in Gliomaâ€"a Systematic Review and Meta-analysis. Molecular Neurobiology, 2018, 55, 3718-3724.	1.9	31

#	Article	IF	Citations
147	Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma. Cancer, 2017, 123, 2118-2129.	2.0	121
148	BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma. Clinical Cancer Research, 2017, 23, 5631-5638.	3.2	56
149	Control of cell death and mitochondrial fission by <scp>ERK</scp>1/2 <scp>MAP</scp> kinase signalling. FEBS Journal, 2017, 284, 4177-4195.	2.2	147
150	ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells. Molecular Cancer, 2017, 16, 102.	7.9	108
151	High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. Cancer Discovery, 2017, 7, 586-595.	7.7	554
152	Molecular genetic and immunotherapeutic targets in metastatic melanoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 281-293.	1.4	16
153	Immunohistochemistry as an accurate tool for evaluating BRAF-V600E mutation in 130 samples of papillary thyroid cancer. Surgery, 2017, 161, 1122-1128.	1.0	26
154	Multi-recurrent invasive ameloblastoma: A surgical challenge. International Journal of Surgery Case Reports, 2017, 30, 43-45.	0.2	12
155	RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition. Nature Communications, 2017, 8, 1211.	5.8	65
156	New perspectives for targeting RAF kinase in human cancer. Nature Reviews Cancer, 2017, 17, 676-691.	12.8	285
157	Copper Chelation Inhibits BRAFV600E-Driven Melanomagenesis and Counters Resistance to BRAFV600E and MEK1/2 Inhibitors. Cancer Research, 2017, 77, 6240-6252.	0.4	98
158	SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer. Annals of Oncology, 2017, 28, 3028-3036.	0.6	25
159	DAN (NBL1) promotes collective neural crest migration by restraining uncontrolled invasion. Journal of Cell Biology, 2017, 216, 3339-3354.	2.3	27
160	Somatic mutation analysis in melanoma using targeted next generation sequencing. Experimental and Molecular Pathology, 2017, 103, 172-177.	0.9	19
161	NRAS-driven melanoma: A RAF can hide another. Molecular and Cellular Oncology, 2017, 4, e1344758.	0.3	3
162	BIK is involved in BRAF/MEK inhibitor induced apoptosis in melanoma cell lines. Cancer Letters, 2017, 404, 70-78.	3.2	9
163	CDCP1 drives triple-negative breast cancer metastasis through reduction of lipid-droplet abundance and stimulation of fatty acid oxidation. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E6556-E6565.	3.3	134
164	Critical role of gliomaâ€associated oncogene homolog 1 in maintaining invasive and mesenchymalâ€like properties of melanoma cells. Cancer Science, 2017, 108, 1602-1611.	1.7	16

#	Article	IF	Citations
165	The Many Faces of the Paradoxical Response to BRAF Inhibitors. Clinical Skin Cancer, 2017, 2, 39-43.	0.1	0
166	Mutational analysis of the RAS/RAF/MEK/ERK signaling pathway in 260 Han Chinese patients with cervical carcinoma. Oncology Letters, 2017, 14, 2427-2431.	0.8	12
167	MicroRNA-605 functions as a tumor suppressor by targeting INPP4B in melanoma. Oncology Reports, 2017, 38, 1276-1286.	1.2	28
168	Piconewtonâ€Scale Analysis of Rasâ€BRaf Signal Transduction with Singleâ€Molecule Force Spectroscopy. Small, 2017, 13, 1701972.	5.2	3
169	Parameterization of Palmitoylated Cysteine, Farnesylated Cysteine, Geranylgeranylated Cysteine, and Myristoylated Glycine for the Martini Force Field. Journal of Physical Chemistry B, 2017, 121, 11132-11143.	1.2	33
170	Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma. Oncologist, 2017, 22, 823-833.	1.9	69
171	The value of prior knowledge in machine learning of complex network systems. Bioinformatics, 2017, 33, 3610-3618.	1.8	17
172	RAS Proteins and Their Regulators in Human Disease. Cell, 2017, 170, 17-33.	13.5	1,262
173	Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to date. Therapeutic Advances in Medical Oncology, 2017, 9, 481-492.	1.4	45
174	Therapeutic Potential of Small Molecule Inhibitors. Journal of Cellular Biochemistry, 2017, 118, 959-961.	1.2	23
175	Suppression of B-Raf^{V600E} melanoma cell survival by targeting mitochondria using triphenyl-phosphonium-conjugated nitroxide or ubiquinone. Cancer Biology and Therapy, 2017, 18, 106-114.	1.5	20
176	Sequence analysis of <scp>RAS</scp> and <scp>RAF</scp> mutation hot spots in canine carcinoma. Veterinary and Comparative Oncology, 2017, 15, 1598-1605.	0.8	18
177	Risk of Ophthalmic Adverse Effects in Patients Treated with MEK Inhibitors: A Systematic Review and Meta-Analysis. Ophthalmic Research, 2017, 57, 60-69.	1.0	14
178	Kinase gene fusions in defined subsets of melanoma. Pigment Cell and Melanoma Research, 2017, 30, 53-62.	1.5	41
179	Determination of A Novel Selective B-RafV600E Inhibitor (LXK4) in Dog Plasma by HPLCâ€“MS/MS and its Application in a Pharmacokinetic Study. Chromatographia, 2017, 80, 71-76.	0.7	0
180	Search for Inhibitors of Ras-Driven Cancers. , 2017, , 135-154.		1
181	Molecular mechanisms supporting a pathogenic role for human polyomavirus 6 small T antigen: Protein phosphatase 2A targeting and MAPK cascade activation. Journal of Medical Virology, 2017, 89, 742-747.	2.5	10
182	mutLBSgeneDB: mutated ligand binding site gene DataBase. Nucleic Acids Research, 2017, 45, D256-D263.	6.5	21

#	Article	IF	Citations
183	MAPK Pathwayâ€“Targeted Therapies: Care and Management of Unique Toxicities in Patients With Advanced Melanoma. Clinical Journal of Oncology Nursing, 2017, 21, 699-709.	0.3	15
184	In Vitro Antiproliferative Activity of Extracts of Carlina acaulis subsp. caulescens and Carlina acanthifolia subsp. utzka. Frontiers in Pharmacology, 2017, 8, 371.	1.6	22
185	Animal Models of Skin Disorders. , 2017, , 357-375.		9
186	Targeted drugs and diagnostic assays Companions in the race to combat ethnic disparity. Frontiers in Bioscience - Landmark, 2017, 22, 193-211.	3.0	5
187	microRNA-193a-3p is specifically down-regulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer. BMC Cancer, 2017, 17, 723.	1.1	28
188	Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients. Biomarker Research, 2017, 5, 32.	2.8	33
189	Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib. Oncotarget, 2017, 8, 60094-60108.	0.8	85
190	Combined Targeted Therapy for BRAF-Mutant, Treatment-Related Acute Myeloid Leukemia. JCO Precision Oncology, 2017, 1, 1-7.	1.5	3
191	ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway. , 2018, 187, 45-60.		123
192	Current Insights of BRAF Inhibitors in Cancer. Journal of Medicinal Chemistry, 2018, 61, 5775-5793.	2.9	76
193	In Vivo Phosphoproteome Analysis Reveals Kinome Reprogramming in Hepatocellular Carcinoma. Molecular and Cellular Proteomics, 2018, 17, 1067-1083.	2.5	27
194	Nanomaterials for Cancer Precision Medicine. Advanced Materials, 2018, 30, e1705660.	11.1	136
195	Targeted-gene silencing of BRAF to interrupt BRAF/MEK/ERK pathway synergized photothermal therapeutics for melanoma using a novel FA-GNR-siBRAF nanosystem. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 1679-1693.	1.7	16
196	A new era of proactive melanoma therapy: hit hard, hit early. British Journal of Dermatology, 2018, 178, 817-820.	1.4	7
197	Sorafenib improves alkylating therapy by blocking induced inflammation, invasion and angiogenesis in breast cancer cells. Cancer Letters, 2018, 425, 101-115.	3.2	24
198	Towards actionable health information: the expanding armory of laboratory cancer diagnostics. JDDG - Journal of the German Society of Dermatology, 2018, 16, 399-400.	0.4	0
199	Isoform-selective activity-based profiling of ERK signaling. Chemical Science, 2018, 9, 2419-2431.	3.7	34
200	Targeting Cyclin D-CDK4/6 Sensitizes Immune-Refractory Cancer by Blocking the SCP3â€“NANOG Axis. Cancer Research, 2018, 78, 2638-2653.	0.4	30

#	Article	IF	Citations
201	DNA microarray-based resonance light scattering assay for multiplexed detection of DNA mutation in papillary thyroid cancer. Analyst, The, 2018, 143, 914-919.	1.7	2
202	Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers. Oncogene, 2018, 37, 1775-1787.	2.6	28
203	The novel RAF1 mutation p.(Gly361Ala) located outside the kinase domain of the CR3 region in two patients with Noonan syndrome, including one with a rare brain tumor. American Journal of Medical Genetics, Part A, 2018, 176, 470-476.	0.7	17
204	Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors. Nature Medicine, 2018, 24, 203-212.	15.2	178
205	Unraveling the human protein atlas of metastatic melanoma in the course of ultraviolet radiation-derived photo-therapy. Journal of Proteomics, 2018, 188, 119-138.	1.2	4
206	Auf dem Weg zu â€žactionable Health Informationâ€œ: Das wachsende Arsenal der Labordiagnostik bei Krebserkrankungen. JDDG - Journal of the German Society of Dermatology, 2018, 16, 399-400.	0.4	0
207	Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy. Acta Pharmaceutica Sinica B, 2018, 8, 552-562.	5.7	294
208	Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells. Neoplasia, 2018, 20, 467-477.	2.3	13
209	A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types. Npj Precision Oncology, 2018, 2, 7.	2.3	107
210	BRAF and EGFR inhibitors synergize to increase cytotoxic effects and decrease stem cell capacities in BRAF(V600E)-mutant colorectal cancer cells. Acta Biochimica Et Biophysica Sinica, 2018, 50, 355-361.	0.9	14
211	The safety and efficacy of dabrafenib and trametinib for the treatment of melanoma. Expert Opinion on Drug Safety, 2018, 17, 73-87.	1.0	32
212	Combinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond. American Journal of Clinical Dermatology, 2018, 19, 181-193.	3.3	18
213	FoxM1: Repurposing an oncogene as a biomarker. Seminars in Cancer Biology, 2018, 52, 74-84.	4.3	98
214	Highâ€resolution melting and immunohistochemical analysis efficiently detects mutually exclusive genetic alterations of adamantinomatous and papillary craniopharyngiomas. Neuropathology, 2018, 38, 3-10.	0.7	18
215	Targeting the Architecture of Deregulated Protein Complexes in Cancer. Advances in Protein Chemistry and Structural Biology, 2018, 111, 101-132.	1.0	5
216	A guanine derivative as a new MEK inhibitor produced by Streptomyces sp. MK63-43F2. Journal of Antibiotics, 2018, 71, 135-138.	1.0	5
217	A fine balancing act: A delicate kinase-phosphatase equilibrium that protects against chromosomal instability and cancer. International Journal of Biochemistry and Cell Biology, 2018, 96, 148-156.	1.2	23
219	Combinations of Genomically and Immune-Targeted Therapies in Early-Phase Clinical Trials. Current Cancer Research, 2018, , 243-280.	0.2	0

#	Article	IF	Citations
220	Deconstructing Lipid Kinase Inhibitors by Chemical Proteomics. Biochemistry, 2018, 57, 231-236.	1.2	18
221	BRAF in Lung Cancers: Analysis of Patient Cases Reveals Recurrent BRAF Mutations, Fusions, Kinase Duplications, and Concurrent Alterations. JCO Precision Oncology, 2018, 2, 1-15.	1.5	24
222	Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer. Oncotarget, 2018, 9, 16110-16123.	0.8	25
223	Antiâ€'cancer effects of a novel Panâ€'RAF inhibitor in a hepatocellular carcinoma cell line. Molecular Medicine Reports, 2018, 17, 6185-6193.	1.1	5
224	Mechanisms of Drug Resistance in Cancer Therapy. Handbook of Experimental Pharmacology, 2018, , .	0.9	1
225	Utilization of Reactive Oxygen Species Targeted Therapy to Prolong the Efficacy of BRAF Inhibitors in Melanoma. Journal of Cancer, 2018, 9, 4665-4676.	1.2	20
226	Exploring the efficacy and cellular uptake of sorafenib in colon cancer cells by Raman micro-spectroscopy. Analyst, The, 2018, 143, 6069-6078.	1.7	13
227	Counteracting Resistance to BRAF V600E Mutation in Melanoma Using Dietary Polyphenols. , 2018, , 185-193.		0
228	A new ALK isoform transported by extracellular vesicles confers drug resistance to melanoma cells. Molecular Cancer, 2018, 17, 145.	7.9	54
229	Reviving oncogenic addiction to MET bypassed by BRAF (G469A) mutation. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 10058-10063.	3.3	17
230	The Transcription Factor ETV5 Mediates BRAFV600E-Induced Proliferation and TWIST1 Expression in Papillary Thyroid Cancer Cells. Neoplasia, 2018, 20, 1121-1134.	2.3	32
231	Identification and Biological Evaluation of Novel Typeâ€…II Bâ€RafV600EInhibitors. ChemMedChem, 2018, 13, 2558-2566.	1.6	8
232	Oncogenic mutations in IKKÎ² function through global changes induced by K63-linked ubiquitination and result in autocrine stimulation. PLoS ONE, 2018, 13, e0206014.	1.1	3
233	MEK inhibitors induce apoptosis via FoxO3a-dependent PUMA induction in colorectal cancer cells. Oncogenesis, 2018, 7, 67.	2.1	21
234	From oncogenic mutation to dynamic code. Science, 2018, 361, 844-845.	6.0	6
236	Synthesis and Biological Profiles of 4,5-, 1,5-, and 1,2-Diaryl-1 H -imidazoles. , 2018, , 83-160.		0
237	<scp>CD</scp>47â€signal regulatory protein Î± signaling system and its application to cancer immunotherapy. Cancer Science, 2018, 109, 2349-2357.	1.7	99
238	Principles of Targeted Therapy. , 2018, , 1-15.		0

#	Article	IF	Citations
239	Detection of the Cell Cycle-Regulated Negative Feedback Phosphorylation of Mitogen-Activated Protein Kinases in Breast Carcinoma using Nanofluidic Proteomics. Scientific Reports, 2018, 8, 9991.	1.6	10
240	Targeting signal-transducer-and-activator-of-transcription 3Âsensitizes human cutaneous melanoma cells to BRAF inhibitor. Cancer Biomarkers, 2018, 23, 67-77.	0.8	8
241	The AMPK inhibitor overcomes the paradoxical effect of RAF inhibitors through blocking phosphoâ€“Ser-621 in the C terminus of CRAF. Journal of Biological Chemistry, 2018, 293, 14276-14284.	1.6	15
242	Mutational analysis ofKRASand its clinical implications in cervical cancer patients. Journal of Gynecologic Oncology, 2018, 29, e4.	1.0	25
243	Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy. Cancer Management and Research, 2018, Volume 10, 647-652.	0.9	12
244	The Ashitaba (Angelica keiskei) Chalcones 4-hydroxyderricin and Xanthoangelol Suppress Melanomagenesis By Targeting BRAF and PI3K. Cancer Prevention Research, 2018, 11, 607-620.	0.7	8
245	Mechanism of BRAF Activation through Biochemical Characterization of the Recombinant Fullâ€Length Protein. ChemBioChem, 2018, 19, 1988-1997.	1.3	32
246	Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling. Cell Systems, 2018, 7, 161-179.e14.	2.9	53
247	Reclassification of the BRAF p.Ile208Val variant by case-level data sharing. Journal of Physical Education and Sports Management, 2018, 4, a002675.	0.5	4
249	Targeting oncogenic Raf protein-serine/threonine kinases in human cancers. Pharmacological Research, 2018, 135, 239-258.	3.1	154
250	Translational Research in Cutaneous Melanoma: New Therapeutic Perspectives. Anti-Cancer Agents in Medicinal Chemistry, 2018, 18, 166-181.	0.9	10
251	Prediction of BRAF mutation status of craniopharyngioma using magnetic resonance imaging features. Journal of Neurosurgery, 2018, 129, 27-34.	0.9	35
252	Stachydrine suppresses viability & migration of astrocytoma cells via CXCR4/ERK & CXCR4/Akt pathway activity. Future Oncology, 2018, 14, 1443-1459.	1.1	14
253	Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. Blood Cancer Journal, 2018, 8, 60.	2.8	25
254	Design, synthesis, and biological evaluation of pyrazole derivatives containing acetamide bond as potential BRAF V600E inhibitors. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2382-2390.	1.0	11
255	A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor. Cancer Discovery, 2018, 8, 1130-1141.	7.7	56
256	Development and Verification of an RNA Sequencing (RNA-Seq) Assay for the Detection of Gene Fusions in Tumors. Journal of Molecular Diagnostics, 2018, 20, 495-511.	1.2	36
257	BRAF^{V600E} mutation: A promising target in colorectal neuroendocrine carcinoma. International Journal of Cancer, 2019, 144, 1379-1390.	2.3	33

#	Article	IF	Citations
258	Endoplasmic reticulum stress signalling â€“ from basic mechanisms to clinical applications. FEBS Journal, 2019, 286, 241-278.	2.2	568
259	BRAF inhibitors promote intermediate BRAF(V600E) conformations and binary interactions with activated RAS. Science Advances, 2019, 5, eaav8463.	4.7	25
260	Synthesis and In Vitro Biological Evaluation of New Pyrido[2,3â€•b]pyrazinoneâ€Based Cytotoxic Agents and Molecular Docking as BRAF Inhibitors. ChemistrySelect, 2019, 4, 8882-8885.	0.7	3
261	Principles of Targeted Therapy. , 2019, , 165-179.		0
262	TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAFV600E/TERT promoter double-mutated glioma. Acta Neuropathologica Communications, 2019, 7, 128.	2.4	26
263	ABIN-2, of the TPL-2 Signaling Complex, Modulates Mammalian Inflammation. Trends in Immunology, 2019, 40, 799-808.	2.9	18
264	Upregulation of S100A9 contributes to the acquired resistance to BRAF inhibitors. Genes and Genomics, 2019, 41, 1273-1280.	0.5	5
265	A patent review of RAF kinase inhibitors (2010â€“2018). Expert Opinion on Therapeutic Patents, 2019, 29, 675-688.	2.4	13
266	Catalytically Competent Non-transforming H-RASG12P Mutant Provides Insight into Molecular Switch Function and GAP-independent GTPase Activity of RAS. Scientific Reports, 2019, 9, 10967.	1.6	3
267	Targeting Oncogenic BRAF: Past, Present, and Future. Cancers, 2019, 11, 1197.	1.7	143
268	Human DNA Virus Exploitation of the MAPK-ERK Cascade. International Journal of Molecular Sciences, 2019, 20, 3427.	1.8	48
269	SREBP1-dependent de novo fatty acid synthesis gene expression is elevated in malignant melanoma and represents a cellular survival trait. Scientific Reports, 2019, 9, 10369.	1.6	33
270	Copper chaperone ATOX1 is required for MAPK signaling and growth in BRAF mutation-positive melanoma. Metallomics, 2019, 11, 1430-1440.	1.0	39
271	Understanding the impacts of missense mutations on structures and functions of human cancer-related genes: A preliminary computational analysis of the COSMIC Cancer Gene Census. PLoS ONE, 2019, 14, e0219935.	1.1	10
272	Systematic analysis of the intersection of disease mutations with protein modifications. BMC Medical Genomics, 2019, 12, 109.	0.7	16
273	Cancer cell-derived long pentraxin 3 (PTX3) promotes melanoma migration through a toll-like receptor 4 (TLR4)/NF-ÎºB signaling pathway. Oncogene, 2019, 38, 5873-5889.	2.6	71
274	Cell type-dependent differential activation of ERK by oncogenic KRAS in colon cancer and intestinal epithelium. Nature Communications, 2019, 10, 2919.	5.8	70
275	Transcriptoâ€based network analysis reveals a model of gene activation in tongue squamous cell carcinomas. Head and Neck, 2019, 41, 4098-4110.	0.9	8

#	Article	IF	Citations
276	Analytical Evaluation of an NGS Testing Method for Routine Molecular Diagnostics on Melanoma Formalin-Fixed, Paraffin-Embedded Tumor-Derived DNA. Diagnostics, 2019, 9, 117.	1.3	6
277	Indirubin 3â€²-Oxime Inhibits Migration, Invasion, and Metastasis in Mice Bearing Spontaneously Occurring Pancreatic Cancer via Blocking the RAF/ERK, AKT, and SAPK/JNK Pathways. Translational Oncology, 2019, 12, 1574-1582.	1.7	18
278	Protein Allostery in Drug Discovery. Advances in Experimental Medicine and Biology, 2019, , .	0.8	11
279	Targeting melanomaâ€™s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors. Nature Communications, 2019, 10, 5167.	5.8	52
280	Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside. Cancers, 2019, 11, 1342.	1.7	22
281	Targeting CDC7 sensitizes resistance melanoma cells to BRAFV600E-specific inhibitor by blocking the CDC7/MCM2-7 pathway. Scientific Reports, 2019, 9, 14197.	1.6	22
282	Defining subpopulations of differential drug response to reveal novel target populations. Npj Systems Biology and Applications, 2019, 5, 36.	1.4	18
283	Design, synthesis and biological evaluation of some new 1,3,4-thiadiazine-thiourea derivatives as potential antitumor agents against non-small cell lung cancer cells. Bioorganic Chemistry, 2019, 93, 103323.	2.0	13
284	Systemic MEK inhibition enhances the efficacy of 5-aminolevulinic acid-photodynamic therapy. British Journal of Cancer, 2019, 121, 758-767.	2.9	16
285	Combination of MEK Inhibitor and the JAK2-STAT3 Pathway Inhibition for the Therapy of Colon Cancer. Pathology and Oncology Research, 2019, 25, 769-775.	0.9	19
286	B-Raf deficiency impairs tumor initiation and progression in a murine breast cancer model. Oncogene, 2019, 38, 1324-1339.	2.6	10
287	Dual Inhibitors-Loaded Nanotherapeutics that Target Kinase Signaling Pathways Synergize with Immune Checkpoint Inhibitor. Cellular and Molecular Bioengineering, 2019, 12, 357-373.	1.0	12
288	Extracellular-Signal Regulated Kinase: A Central Molecule Driving Epithelialâ€“Mesenchymal Transition in Cancer. International Journal of Molecular Sciences, 2019, 20, 2885.	1.8	100
289	Drugging K-RasG12C through covalent inhibitors: Mission possible?. , 2019, 202, 1-17.		63
290	BRAF Fusion â€” Another Mechanism of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology, 2019, 14, 764-765.	0.5	3
291	Biochemical Characterization of Fullâ€Length Oncogenic BRAF^{V600E} together with Molecular Dynamics Simulations Provide Insight into the Activation and Inhibition Mechanisms of RAF Kinases. ChemBioChem, 2019, 20, 2850-2861.	1.3	7
292	Inhibiting BRAF Oncogeneâ€“Mediated Radioresistance Effectively Radiosensitizes BRAFV600E-Mutant Thyroid Cancer Cells by Constraining DNA Double-Strand Break Repair. Clinical Cancer Research, 2019, 25, 4749-4760.	3.2	39
293	Low grade serous ovarian carcinoma: identifying variations in practice patterns. International Journal of Gynecological Cancer, 2019, 29, 174-180.	1.2	9

#	Article	IF	Citations
294	Capsaicin-like analogue induced selective apoptosis in A2058 melanoma cells: Design, synthesis and molecular modeling. Bioorganic and Medicinal Chemistry, 2019, 27, 2893-2904.	1.4	16
295	Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers. Journal of Thoracic Oncology, 2019, 14, 802-815.	0.5	71
296	Comparative interactome analysis reveals distinct and overlapping properties of Raf family kinases. Biochemical and Biophysical Research Communications, 2019, 514, 1217-1223.	1.0	5
297	MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance. Nature Communications, 2019, 10, 2030.	5.8	39
298	Developments in the Space of New MAPK Pathway Inhibitors for BRAF-Mutant Melanoma. Clinical Cancer Research, 2019, 25, 5735-5742.	3.2	30
299	BRAF V600E expression in ameloblastomasâ€"A 36â€patient cohort from Helsinki University Hospital. Oral Diseases, 2019, 25, 1169-1174.	1.5	13
300	Gene-Specific Intron Retention Serves as Molecular Signature that Distinguishes Melanoma from Non-Melanoma Cancer Cells in Greek Patients. International Journal of Molecular Sciences, 2019, 20, 937.	1.8	8
301	TP53 mutant cell lines selected for resistance to MDM2 inhibitors retain growth inhibition by MAPK pathway inhibitors but a reduced apoptotic response. Cancer Cell International, 2019, 19, 53.	1.8	9
302	Germline susceptibility variants impact clinical outcome and therapeutic strategies for stage III colorectal cancer. Scientific Reports, 2019, 9, 3931.	1.6	15
303	Nuclear ERK: Mechanism of Translocation, Substrates, and Role in Cancer. International Journal of Molecular Sciences, 2019, 20, 1194.	1.8	121
304	Cardioprotective effects of constitutively active MEK1 against H2O2-induced apoptosis and autophagy in cardiomyocytes via the ERK1/2 signaling pathway. Biochemical and Biophysical Research Communications, 2019, 512, 125-130.	1.0	16
305	Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance. Nature Communications, 2019, 10, 1693.	5.8	119
306	Clinical development of targeted and immune based anti-cancer therapies. Journal of Experimental and Clinical Cancer Research, 2019, 38, 156.	3.5	170
307	Anticancer profile of newly synthesized BRAF inhibitors possess 5-(pyrimidin-4-yl)imidazo[2,1-b]thiazole scaffold. Bioorganic and Medicinal Chemistry, 2019, 27, 2041-2051.	1.4	32
308	Th17 Cells Paradoxical Roles in Melanoma and Potential Application in Immunotherapy. Frontiers in Immunology, 2019, 10, 187.	2.2	41
309	Giant Congenital Melanocytic Nevus Treated With Trametinib. Pediatrics, 2019, 143, .	1.0	38
310	Response to Anti-EGFR Therapy in Patients with BRAF non-V600â€"Mutant Metastatic Colorectal Cancer. Clinical Cancer Research, 2019, 25, 7089-7097.	3.2	79
311	Architecture of autoinhibited and active BRAFâ€"MEK1â€"14-3-3 complexes. Nature, 2019, 575, 545-550.	13.7	197

#	Article	IF	Citations
312	CPEM: Accurate cancer type classification based on somatic alterations using an ensemble of aÂrandom forest and a deep neural network. Scientific Reports, 2019, 9, 16927.	1.6	21
313	An epitranscriptomic mechanism underlies selective mRNA translation remodelling in melanoma persister cells. Nature Communications, 2019, 10, 5713.	5.8	70
314	Developing neoantigen-targeted T cellâ€“based treatments for solid tumors. Nature Medicine, 2019, 25, 1488-1499.	15.2	173
315	The Mutational Profile of Unicystic Ameloblastoma. Journal of Dental Research, 2019, 98, 54-60.	2.5	55
316	Novel Drug Treatments of Progressive Radioiodine-Refractory Differentiated Thyroid Cancer. Endocrinology and Metabolism Clinics of North America, 2019, 48, 253-268.	1.2	18
317	Efficient extraction and isolation of skimmianine from New Caledonian plant Medicosma leratii and evaluation of its effects on apoptosis, necrosis, and autophagy. Phytochemistry Letters, 2019, 30, 224-230.	0.6	8
318	Clinicopathological and Molecular Characteristics of Mammary Adenoid Cystic Carcinoma With Adipocytic Differentiation With Emphasis on the Identification of a Novel BRAF Mutation. Anticancer Research, 2019, 39, 369-374.	0.5	12
319	Targeting MEK in vemurafenib-resistant hairy cell leukemia. Leukemia, 2019, 33, 541-545.	3.3	26
320	Signal transducer and activator of transcription 3 inhibition enhances vemurafenib sensitivity in colon cancers harboring the BRAF^{V600E} mutation. Journal of Cellular Biochemistry, 2019, 120, 5315-5325.	1.2	8
321	Comprehensive pancancer genomic analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in cancer: Its clinical implications. Seminars in Cancer Biology, 2019, 54, 14-28.	4.3	51
322	Clinical trials, progression-speed differentiating features and swiftness rule of the innovative targets of first-in-class drugs. Briefings in Bioinformatics, 2020, 21, 649-662.	3.2	139
323	Overview of Molecular Testing of Cytology Specimens. Acta Cytologica, 2020, 64, 136-146.	0.7	24
324	Mutational Profile Using Next-Generation Sequencing May Aid in the Diagnosis and Treatment of Urachal Adenocarcinoma. International Journal of Surgical Pathology, 2020, 28, 51-59.	0.4	6
325	Comparative analysis of the phototoxicity induced by BRAF inhibitors and alleviation through antioxidants. Photodermatology Photoimmunology and Photomedicine, 2020, 36, 126-134.	0.7	6
326	BRAF inhibitor treatment in classic hairy cell leukemia: a long-term follow-up study of patients treated outside clinical trials. Leukemia, 2020, 34, 1454-1457.	3.3	16
327	An evaluation of encorafenib for the treatment of melanoma. Expert Opinion on Pharmacotherapy, 2020, 21, 155-161.	0.9	11
328	Quantification of ERK Kinase Activity in Biological Samples Using Differential Sensing. ACS Chemical Biology, 2020, 15, 83-92.	1.6	12
330	Significance of Tumor Mutation Burden in Immune Infiltration and Prognosis in Cutaneous Melanoma. Frontiers in Oncology, 2020, 10, 573141.	1.3	63

#	Article	IF	Citations
331	Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review. Cancers, 2020, 12, 2801.	1.7	73
332	Adverse Drug Events in the Oral Cavity. Dermatologic Clinics, 2020, 38, 523-533.	1.0	10
333	Transmissible Endoplasmic Reticulum Stress: A Novel Perspective on Tumor Immunity. Frontiers in Cell and Developmental Biology, 2020, 8, 846.	1.8	17
334	Adaptive redox homeostasis in cutaneous melanoma. Redox Biology, 2020, 37, 101753.	3.9	37
335	New Insights into Diffuse Large B-Cell Lymphoma Pathobiology. Cancers, 2020, 12, 1869.	1.7	41
336	Rapid BRAF Mutation Testing in Pigmented Melanomas. American Journal of Dermatopathology, 2020, 42, 343-348.	0.3	7
337	Mutation-oriented profiling of autoinhibitory kinase conformations predicts RAF inhibitor efficacies. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 31105-31113.	3.3	9
338	The Role of BRAF in Metastatic Colorectal Carcinomaâ€“Past, Present, and Future. International Journal of Molecular Sciences, 2020, 21, 9001.	1.8	8
339	Natural Compounds Play Therapeutic Roles in Various Human Pathologies via Regulating Endoplasmic Reticulum Pathway. Medicine in Drug Discovery, 2020, 8, 100065.	2.3	10
340	Identification of synthetic chemosensitivity genes paired with BRAF for BRAF/MAPK inhibitors. Scientific Reports, 2020, 10, 20001.	1.6	2
341	Hydroxynaphthalenecarboxamides and substituted piperazinylpropandiols, two new series of BRAF inhibitors. A theoretical and experimental study. Bioorganic Chemistry, 2020, 103, 104145.	2.0	8
342	Oncogenic mutations within the Î²3â€Î±C loop of EGFR/ERBB2/BRAF/MAP2K1 predict response to therapies. Molecular Genetics & Genomic Medicine, 2020, 8, e1395.	0.6	10
343	The MAP kinase signal transduction pathway: promising therapeutic targets used in the treatment of melanoma. Expert Review of Anticancer Therapy, 2020, 20, 687-701.	1.1	6
344	Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations. International Journal of Molecular Sciences, 2020, 21, 7649.	1.8	6
345	Extracellular signal-regulated kinases associate with and phosphorylate DHPS to promote cell proliferation. Oncogenesis, 2020, 9, 85.	2.1	5
346	Novel Imidazo[2,1-b]oxazole Derivatives Inhibit Epithelial Cell Transformation and Triple Negative Breast Cancer Tumorigenesis. Anticancer Research, 2020, 40, 5081-5090.	0.5	4
347	The Role of Proteoglycans in Cancer Metastasis and Circulating Tumor Cell Analysis. Frontiers in Cell and Developmental Biology, 2020, 8, 749.	1.8	49
348	Inhibitors of BRAF dimers using an allosteric site. Nature Communications, 2020, 11, 4370.	5.8	48

#	Article	IF	Citations
349	Achieving High Levels of Selectivity for Kinase Inhibitors. Topics in Medicinal Chemistry, 2020, , 95-123.	0.4	0
350	B-Raf-Mutated Melanoma. , 2020, , .		0
351	BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation. Cancers, 2020, 12, 3236.	1.7	23
352	Multivalent assembly of KRAS with the RAS-binding and cysteine-rich domains of CRAF on the membrane. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 12101-12108.	3.3	46
353	Quest for Clinically Effective RAF Dimer Inhibitors. Journal of Clinical Oncology, 2020, 38, 2197-2200.	0.8	5
354	DNA damage and repair scenario in ameloblastoma. Oral Oncology, 2020, 108, 104804.	0.8	10
355	Loss of HAT1 expression confers BRAFV600E inhibitor resistance to melanoma cells by activating MAPK signaling via IGF1R. Oncogenesis, 2020, 9, 44.	2.1	20
356	Histology-agnostic drug development â€" considering issues beyond the tissue. Nature Reviews Clinical Oncology, 2020, 17, 555-568.	12.5	60
357	Discovering and validating cancer genetic dependencies: approaches and pitfalls. Nature Reviews Genetics, 2020, 21, 671-682.	7.7	41
358	The suppressive effect of dabrafenib, a therapeutic agent for metastatic melanoma, in IgE-mediated allergic inflammation. International Immunopharmacology, 2020, 83, 106398.	1.7	2
359	PTPN11 mutations in canine and human disseminated histiocytic sarcoma. International Journal of Cancer, 2020, 147, 1657-1665.	2.3	14
360	Neoantigens in Hematologic Malignancies. Frontiers in Immunology, 2020, 11, 121.	2.2	26
361	The proprotein convertase furin is a pro-oncogenic driver in KRAS and BRAF driven colorectal cancer. Oncogene, 2020, 39, 3571-3587.	2.6	34
362	Inhibition of BCL2 Family Members Increases the Efficacy of Copper Chelation in BRAFV600E-Driven Melanoma. Cancer Research, 2020, 80, 1387-1400.	0.4	29
363	Discovery of a Novel Dual-Target Inhibitor of ERK1 and ERK5 That Induces Regulated Cell Death to Overcome Compensatory Mechanism in Specific Tumor Types. Journal of Medicinal Chemistry, 2020, 63, 3976-3995.	2.9	28
364	Prognostic Biomarkers for Melanoma Immunotherapy. Current Oncology Reports, 2020, 22, 25.	1.8	13
365	Dual-Mechanism ERK1/2 Inhibitors Exploit a Distinct Binding Mode to Block Phosphorylation and Nuclear Accumulation of ERK1/2. Molecular Cancer Therapeutics, 2020, 19, 525-539.	1.9	14
366	Colorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF Variants. Trends in Cancer, 2020, 6, 111-129.	3.8	9

#	Article	IF	Citations
367	Is rituximab therapy a risk factor for development of melanoma?. Dermatologic Therapy, 2020, 33, e13471.	0.8	3
368	RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in Kâ€RAS mutant tumors. Molecular Oncology, 2020, 14, 1833-1849.	2.1	24
369	Detection of an IGH-BRAF fusion in a patient with BRAF Val600Glu negative hairy cell leukemia. Leukemia and Lymphoma, 2020, 61, 2024-2026.	0.6	6
370	BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer. ESMO Open, 2020, 5, e000624.	2.0	15
371	Tracking the expression of therapeutic protein targets in rare cells by antibody-mediated nanoparticle labelling and magnetic sorting. Nature Biomedical Engineering, 2021, 5, 41-52.	11.6	40
372	Targetable BRAF and RAF1 Alterations in Advanced Pediatric Cancers. Oncologist, 2021, 26, e153-e163.	1.9	14
373	PI3K Driver Mutations: A Biophysical Membrane-Centric Perspective. Cancer Research, 2021, 81, 237-247.	0.4	26
374	The therapeutic potential of PROTACs. Expert Opinion on Therapeutic Patents, 2021, 31, 1-24.	2.4	29
375	Affinity maturation of the RLIP76 Ral binding domain to inform the design of stapled peptides targeting the Ral GTPases. Journal of Biological Chemistry, 2021, 296, 100101.	1.6	5
376	AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib. Molecular Cancer Therapeutics, 2021, 20, 238-249.	1.9	13
377	Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer. Trends in Cancer, 2021, 7, 410-429.	3.8	13
378	Molecular Docking Strategy to Design Novel V600E-BRAF Kinase Inhibitors with Prediction of Their Drug-Likeness and Pharmacokinetics ADMET Properties. Chemistry Africa, 2021, 4, 189-205.	1.2	1
379	Mutational drivers of cancer cell migration and invasion. British Journal of Cancer, 2021, 124, 102-114.	2.9	101
380	A CRISPR-Cas9 repressor for epigenetic silencing of KRAS. Pharmacological Research, 2021, 164, 105304.	3.1	17
381	Senescence in RASopathies, a possible novel contributor to a complex pathophenoype. Mechanisms of Ageing and Development, 2021, 194, 111411.	2.2	8
382	Prognostic Role of BRAF Mutation in Low-Grade Gliomas: Meta-analysis. World Neurosurgery, 2021, 147, 42-46.	0.7	2
383	Massively parallel sequencing analysis of 68 gastric-type cervical adenocarcinomas reveals mutations in cell cycle-related genes and potentially targetable mutations. Modern Pathology, 2021, 34, 1213-1225.	2.9	28
384	Design, synthesis, and biological evaluation of novel imidazole derivatives possessing terminal sulphonamides as potential BRAFV600Einhibitors. Bioorganic Chemistry, 2021, 106, 104508.	2.0	20

#	Article	IF	Citations
385	Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review. Biochimica Et Biophysica Acta - General Subjects, 2021, 1865, 129736.	1.1	38
386	The mechanism of activation of monomeric B-Raf V600E. Computational and Structural Biotechnology Journal, 2021, 19, 3349-3363.	1.9	38
387	Subtype-dependent difference of glucose transporter 1 and hexokinase II expression in craniopharyngioma: an immunohistochemical study. Scientific Reports, 2021, 11, 126.	1.6	2
388	Novel genetic characteristics of multifocal micronodular pneumocyte hyperplasia (MMPH): a case report with frequent BRAF mutations analyzed by next-generation sequencing supporting benign behaviors of MMPH. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 637-641.	1.4	1
389	Molecular Mechanisms of Epithelial to Mesenchymal Transition Regulated by ERK5 Signaling. Biomolecules, 2021, 11, 183.	1.8	13
390	Synthesis and anti-hepatocellular carcinoma activity of aminopyridinolâ€“sorafenib hybrids. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 1884-1897.	2.5	1
391	Pre- and Post-Treatment Imaging of Primary Central Nervous System Tumors in the Molecular and Genetic Era. Korean Journal of Radiology, 2021, 22, 1858-1874.	1.5	4
392	Thymic Adenocarcinoma with Positivity for Thyroid Transcription Factor-1 and a BRAF V600E Mutation: A Case Report. Internal Medicine, 2021, , .	0.3	0
393	LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells. International Journal of Medical Sciences, 2021, 18, 1456-1464.	1.1	19
394	Drug resistance in targeted cancer therapies with RAF inhibitors. , 2021, 4, 665-683.		9
395	Inhibition of Nonfunctional Ras. Cell Chemical Biology, 2021, 28, 121-133.	2.5	23
396	Downregulation of SOX2 by inhibition of Usp9X induces apoptosis in melanoma. Oncotarget, 2021, 12, 160-172.	0.8	8
397	Mutant-selective degradation by BRAF-targeting PROTACs. Nature Communications, 2021, 12, 920.	5.8	71
398	Tumour-Agnostic Therapy for Pancreatic Cancer and Biliary Tract Cancer. Diagnostics, 2021, 11, 252.	1.3	2
399	Differential Sensitivity of Wild-Type and BRAF-Mutated Cells to Combined BRAF and Autophagy Inhibition. Biomolecules and Therapeutics, 2021, 29, 434-444.	1.1	5
400	A Theranostic Cellulose Nanocrystalâ€Based Drug Delivery System with Enhanced Retention in Pulmonary Metastasis of Melanoma. Small, 2021, 17, e2007705.	5.2	24
401	Effect of Metformin in Combination With Trametinib and Paclitaxel on Cell Survival and Metastasis in Melanoma Cells. Anticancer Research, 2021, 41, 1387-1399.	0.5	3
402	Personalized treatment for differentiated thyroid cancer: current data and new perspectives. Minerva Endocrinology, 2021, 46, 62-89.	0.6	6

#	Article	IF	Citations
403	KRAS, YWHAE, SP1 and MSRA as biomarkers in endometrial cancer. Translational Cancer Research, 2021, 10, 1295-1312.	0.4	7
404	Selective CRAF Inhibition Elicits Transactivation. Journal of the American Chemical Society, 2021, 143, 4600-4606.	6.6	15
405	Playing the Whack-A-Mole Game: ERK5 Activation Emerges Among the Resistance Mechanisms to RAF-MEK1/2-ERK1/2- Targeted Therapy. Frontiers in Cell and Developmental Biology, 2021, 9, 647311.	1.8	13
406	Resistance to Molecularly Targeted Therapies in Melanoma. Cancers, 2021, 13, 1115.	1.7	36
408	Allosteric Kinase Inhibitors Reshape MEK1 Kinase Activity Conformations in Cells and In Silico. Biomolecules, 2021, 11, 518.	1.8	4
409	Mutational profile of skin lesions in hepatocellular carcinoma patients under tyrosine kinase inhibition: a repercussion of a wide-spectrum activity. Oncotarget, 2021, 12, 440-449.	0.8	1
410	From Proteomic Mapping to Invasion-Metastasis-Cascade Systemic Biomarkering and Targeted Drugging of Mutant BRAF-Dependent Human Cutaneous Melanomagenesis. Cancers, 2021, 13, 2024.	1.7	5
411	Sensitivity of Oncogenic KRAS-Expressing Cells to CDK9 Inhibition. SLAS Discovery, 2021, 26, 922-932.	1.4	1
413	Acacetin and pinostrobin as a promising inhibitor of cancer-associated protein kinases. Food and Chemical Toxicology, 2021, 151, 112091.	1.8	17
414	A structural perspective on targeting the <scp>RTK</scp>/Ras/<scp>MAP</scp> kinase pathway in cancer. Protein Science, 2021, 30, 1535-1553.	3.1	17
415	Many Distinct Ways Lead to Drug Resistance in BRAF- and NRAS-Mutated Melanomas. Life, 2021, 11, 424.	1.1	3
416	Effect of melanoma stem cells on melanoma metastasis (Review). Oncology Letters, 2021, 22, 566.	0.8	13
417	Targeting the p300/NONO axis sensitizes melanoma cells to BRAF inhibitors. Oncogene, 2021, 40, 4137-4150.	2.6	12
418	The stability of R-spine defines RAF inhibitor resistance: A comprehensive analysis of oncogenic BRAF mutants with in-frame insertion of Î±C-Î²4 loop. Science Advances, 2021, 7, .	4.7	13
419	Opportunities and Challenges of Small Molecule Induced Targeted Protein Degradation. Frontiers in Cell and Developmental Biology, 2021, 9, 685106.	1.8	31
420	Effects of molecular markers on the treatment decision and prognosis of colorectal cancer: a narrative review. Journal of Gastrointestinal Oncology, 2021, 12, 1191-1196.	0.6	8
421	Antitumor Effect of Metformin in Combination with Binimetinib on Melanoma Cells. Development & Reproduction, 2021, 25, 93-104.	0.1	1
422	Research progress of MEK1/2 inhibitors and degraders in the treatment of cancer. European Journal of Medicinal Chemistry, 2021, 218, 113386.	2.6	29

#	Article	IF	Citations
423	Association of BRAF V600E mutations with vasoactive intestinal peptide syndrome in MYCNâ€amplified neuroblastoma. Pediatric Blood and Cancer, 2021, 68, e29265.	0.8	7
424	B-Raf autoinhibition in the presence and absence of 14-3-3. Structure, 2021, 29, 768-777.e2.	1.6	26
425	Cancer - dysregulation of the cell cycle and transduction of cascade signals. Romanian Journal of Rhinology, 2021, 11, 90-100.	0.1	0
426	Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma. Molecular Cancer Therapeutics, 2021, 20, 2177-2188.	1.9	13
427	The Evolution of Acquired Resistance to BRAFV600EÂkinase inhibitor Is Sustained by IGF1-Driven Tumor Vascular Remodeling. Journal of Investigative Dermatology, 2022, 142, 445-458.	0.3	11
429	Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us. Trends in Cancer, 2021, 7, 823-836.	3.8	32
430	Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition. Kidney International, 2021, 100, 1214-1226.	2.6	16
431	Recent developments in mitogen activated protein kinase inhibitors as potential anticancer agents. Bioorganic Chemistry, 2021, 114, 105161.	2.0	11
432	Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study. British Journal of Cancer, 2021, 125, 1261-1269.	2.9	14
433	An Efficient Second-Generation Manufacturing Process for the pan-RAF Inhibitor Belvarafenib. Organic Process Research and Development, 2021, 25, 2338-2350.	1.3	6
434	Allosteric MEK inhibitors act on BRAF/MEK complexes to block MEK activation. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	23
435	Tumors, tumor therapies, autoimmunity and the eye. Autoimmunity Reviews, 2021, 20, 102892.	2.5	7
436	Acute kidney injury in cancer patients. Clinical and Experimental Nephrology, 2022, 26, 103-112.	0.7	3
437	Identification of genes and pathways leading to metastasis and poor prognosis in melanoma. Aging, 2021, 13, 22474-22489.	1.4	3
438	Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?. Npj Breast Cancer, 2021, 7, 120.	2.3	9
440	Cul4b Promotes Progression of Malignant Cutaneous Melanoma Patients by Regulating CDKN2A. Tohoku Journal of Experimental Medicine, 2021, 254, 33-39.	0.5	1
441	Tetrahedral Framework Nucleic Acids Loaded with Aptamer AS1411 for siRNA Delivery and Gene Silencing in Malignant Melanoma. ACS Applied Materials & Interfaces, 2021, 13, 6109-6118.	4.0	52
443	Allosteric Small-Molecule Serine/Threonine Kinase Inhibitors. Advances in Experimental Medicine and Biology, 2019, 1163, 253-278.	0.8	18

#	Article	IF	Citations
444	PDK1: At the crossroad of cancer signaling pathways. Seminars in Cancer Biology, 2018, 48, 27-35.	4.3	130
445	Inhibition of RAF dimers: it takes two to tango. Biochemical Society Transactions, 2021, 49, 237-251.	1.6	35
449	MAP-Kinase-Driven Hematopoietic Neoplasms: A Decade of Progress in the Molecular Age. Cold Spring Harbor Perspectives in Medicine, 2021, 11, a034892.	2.9	17
450	Antitumor Activity of Combination Therapy with Metformin and Trametinib in Non-Small Cell Lung Cancer Cells. Development & Reproduction, 2020, 24, 113-123.	0.1	14
451	Immunotherapy in the Precision Medicine Era: Melanoma and Beyond. PLoS Medicine, 2016, 13, e1002196.	3.9	21
452	Deep-proteome mapping of WM-266-4 human metastatic melanoma cells: From oncogenic addiction to druggable targets. PLoS ONE, 2017, 12, e0171512.	1.1	21
453	Ancient genes establish stress-induced mutation as a hallmark of cancer. PLoS ONE, 2017, 12, e0176258.	1.1	33
454	Modeling of signaling crosstalk-mediated drug resistance and its implications on drug combination. Oncotarget, 2016, 7, 63995-64006.	0.8	43
455	The anti-apoptotic BAG3 protein is involved in BRAF inhibitor resistance in melanoma cells. Oncotarget, 2017, 8, 80393-80404.	0.8	16
456	Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways. Oncotarget, 2017, 8, 84697-84713.	0.8	38
457	PIK3CAH1047R-induced paradoxical ERK activation results in resistance to BRAFV600E specific inhibitors in BRAFV600E PIK3CAH1047R double mutant thyroid tumors. Oncotarget, 2017, 8, 103207-103222.	0.8	18
458	Copy number variations in atypical fibroxanthomas and pleomorphic dermal sarcomas. Oncotarget, 2017, 8, 109457-109467.	0.8	32
459	BRAF-mutant hematopoietic malignancies. Oncotarget, 2014, 5, 7980-7981.	0.8	3
460	In vivo quantification and perturbation of Myc-Max interactions and the impact on oncogenic potential. Oncotarget, 2014, 5, 8869-8878.	0.8	27
461	Targeted therapies for advanced non-small cell lung cancer. Oncotarget, 2018, 9, 37589-37607.	0.8	52
462	Ferroxitosis: A cell death from modulation of oxidative phosphorylation and PKM2-dependent glycolysis in melanoma. Oncotarget, 2014, 5, 12694-12703.	0.8	13
463	Molecular stratification of metastatic melanoma using gene expression profiling : Prediction of survival outcome and benefit from molecular targeted therapy. Oncotarget, 2015, 6, 12297-12309.	0.8	148
464	Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b. Oncotarget, 2016, 7, 4428-4441.	0.8	84

#	Article	IF	Citations
465	Validation of a preclinical model for assessment of drug efficacy in melanoma. Oncotarget, 2016, 7, 13069-13081.	0.8	12
466	Suppression of B-Raf(V600E) cancers by MAPK hyper-activation. Oncotarget, 2016, 7, 18694-18704.	0.8	11
467	ARF1 promotes prostate tumorigenesis via targeting oncogenic MAPK signaling. Oncotarget, 2016, 7, 39834-39845.	0.8	43
468	FAM83 proteins: Fostering new interactions to drive oncogenic signaling and therapeutic resistance. Oncotarget, 2016, 7, 52597-52612.	0.8	45
469	Mechanistic target of rapamycin inhibitors: successes and challenges as cancer therapeutics. , 2019, 2, 1069-1085.		11
470	An update on molecular alterations in melanocytic tumors with emphasis on Spitzoid lesions. Annals of Translational Medicine, 2018, 6, 249-249.	0.7	24
471	New Perspectives in the Pharmacological Treatment of Non-Melanoma Skin Cancer. Current Drug Targets, 2016, 17, 353-374.	1.0	8
472	Phytochemicals for the Management of Melanoma. Mini-Reviews in Medicinal Chemistry, 2016, 16, 953-979.	1.1	62
473	Inhibition of Galectin-1 Sensitizes HRAS-driven Tumor Growth to Rapamycin Treatment. Anticancer Research, 2016, 36, 5053-5062.	0.5	17
474	Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity. International Journal of Molecular Sciences, 2020, 21, 1102.	1.8	408
475	ERK/MAPK signalling pathway and tumorigenesis (Review). Experimental and Therapeutic Medicine, 2020, 19, 1997-2007.	0.8	670
476	Impact of BRAF mutation status in the prognosis of cutaneous melanoma: an area of ongoing research. Annals of Translational Medicine, 2015, 3, 24.	0.7	31
477	Melanoma: oncogenic drivers and the immune system. Annals of Translational Medicine, 2015, 3, 265.	0.7	19
478	Induction of Resistance to BRAF Inhibitor Is Associated with the Inability of Spry2 to Inhibit BRAF-V600E Activity in BRAF Mutant Cells. Biomolecules and Therapeutics, 2015, 23, 320-326.	1.1	14
479	Differential Gene Expression Common to Acquired and Intrinsic Resistance to BRAF Inhibitor Revealed by RNA-Seq Analysis. Biomolecules and Therapeutics, 2019, 27, 302-310.	1.1	19
480	PLGA-loaded nanomedicines in melanoma treatment: Future prospect for efficient drug delivery. Indian Journal of Medical Research, 2016, 144, 181.	0.4	13
481	The hallmarks of cancer and their therapeutic targeting in current use and clinical trials. Iraqi Journal of Hematology, 2020, 9, 1.	0.0	6
482	Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF. Cancer Research and Treatment, 2017, 49, 947-959.	1.3	41

#	Article	IF	Citations
483	Epidermal RAF prevents allergic skin disease. ELife, 2016, 5, .	2.8	14
484	Targeted Therapy for BRAF Mutant Brain Tumors. Current Treatment Options in Oncology, 2021, 22, 105.	1.3	4
485	Small Molecule Kinase Inhibitor Drugs (1995â€“2021): Medical Indication, Pharmacology, and Synthesis. Journal of Medicinal Chemistry, 2022, 65, 1047-1131.	2.9	114
486	Low Grade Serous Ovarian Cancer: Is disturbed Receptor Ratio (ER: PgR) an Etiogenic Factor?. Indian Journal of Gynecologic Oncology, 2021, 19, 1.	0.1	1
487	Crystallization of the Multi-Receptor Tyrosine Kinase Inhibitor Sorafenib for Controlled Long-Term Drug Delivery Following a Single Injection. Cellular and Molecular Bioengineering, 2021, 14, 471-486.	1.0	0
488	The copper chaperone CCS facilitates copper binding to MEK1/2 to promote kinase activation. Journal of Biological Chemistry, 2021, 297, 101314.	1.6	21
489	Increase in the sensitivity to PLX4720 through inhibition of transcription factor EB-dependent autophagy in BRAF inhibitor-resistant cells. Toxicological Research, 2022, 38, 35-44.	1.1	3
490	Computational Exploration of Anti-Cancer Potential of GUAIANE Dimers from Xylopia vielana by Targeting B-Raf Kinase Using Chemo-Informatics, Molecular Docking, and MD Simulation Studies. Anti-Cancer Agents in Medicinal Chemistry, 2022, 22, 731-746.	0.9	23
492	Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers. Cancers, 2021, 13, 5059.	1.7	39
493	Mitogen-Activated Protein Kinase Signaling and Cancer. , 2015, , 211-231.		0
494	A new role for an old enemy. ELife, 2015, 4, e06424.	2.8	0
495	Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures. Oncotarget, 2015, 6, 25452-25465.	0.8	3
496	The Impact of Cancer Treatments on Aging. , 2016, , 85-119.		0
497	Targeted Cancer Therapy. Nishinihon Journal of Dermatology, 2016, 78, 221-228.	0.0	0
498	Future Role of Molecular Profiling in Small Breast Samples and Personalised Medicine. , 2016, , 803-817.		0
499	BRAF Mutations. , 2016, , 4-16-4-17.		0
500	Preventative and Personalized Approach to the Treatment of Malignant Melanoma: A Case Report.. University of Ottawa Journal of Medicine, 2016, 6, 49-52.	0.0	0
506	Oncoyeasti: a web-based application to translate data obtained from Saccharomyces cerevisiae high-throughput drug screens into cancer therapeutics. F1000Research, 0, 7, 757.	0.8	0

#	Article	IF	Citations
509	Successful targeted therapy in a patient with transformation of a BRAF-mutated ameloblastoma into an undifferentiated round-cell sarcoma. Russian Journal of Pediatric Hematology and Oncology, 2019, 5, 86-93.	0.1	0
510	Resistance to ERK1/2 pathway inhibitors; sweet spots, fitness deficits and drug addiction. , 2019, 2, 365-380.		3
511	The role of tumor stem cells in the development of drug resistance of melanoma. , 2019, 18, 6-14.	0.3	3
512	Bioinformatic pipelines for whole transcriptome sequencing data exploitation in leukemia patients with complex structural variants. PeerJ, 2019, 7, e7071.	0.9	1
514	Emerging Importance of Tyrosine Kinase Inhibitors against Cancer: Quo Vadis to Cure?. International Journal of Molecular Sciences, 2021, 22, 11659.	1.8	18
515	Immunohistochemistry as an accurate tool for the assessment of BRAF V600E and TP53 mutations in primary and metastatic melanoma. Molecular and Clinical Oncology, 2021, 15, 270.	0.4	3
517	The Role of BRAF Gene in Cancer: Literature Review and Future Directions. Journal of Cancer Research Updates, 2020, 9, 11-19.	0.3	1
518	VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives. European Journal of Medicinal Chemistry, 2022, 227, 113906.	2.6	27
519	Mass spectrometry for human kinome analysis. , 2022, , 191-216.		1
520	Chemical Probes for Kinases. Chemical Biology, 2020, , 182-213.	0.1	0
521	Regulation of Mitogen-Activated Protein Kinase Signaling Pathways by the Ubiquitin-Proteasome System and Its Pharmacological Potential. Pharmacological Reviews, 2021, 73, 1434-1467.	7.1	12
522	Mutational analysis of KRAS and its clinical implications in cervical cancer patients. Journal of Gynecologic Oncology, 0, 29, .	1.0	0
523	In silico evaluation of some 4-(quinolin-2-yl)pyrimidin-2-amine derivatives as potent V600E-BRAF inhibitors with pharmacokinetics ADMET and drug-likeness predictions. Future Journal of Pharmaceutical Sciences, 2020, 6, .	1.1	10
525	Computational evaluation of potent 2-(1H-imidazol-2-yl) pyridine derivatives as potential V600E-BRAF inhibitors. Egyptian Journal of Medical Human Genetics, 2020, 21, .	0.5	10
526	Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options. Cancer Biology and Medicine, 2016, 13, 77-86.	1.4	9
529	Targeting STAT3 restores BRAF inhibitor sensitivity through miR-759-3p in human cutaneous melanoma cells. International Journal of Clinical and Experimental Pathology, 2018, 11, 2550-2560.	0.5	1
530	Management of nephrotoxicity of chemotherapy and targeted agents: 2020. American Journal of Cancer Research, 2020, 10, 4151-4164.	1.4	4
531	ÐžÑÐ½Ð¾Ð²Ð°Ð½Ð½Ñ‹Ðµ Ð½Ð° Ð¼Ð¾Ð»ÐµÐºÑƒÐ»Ñ€Ð½Ð¾Ð¼ Ð¿Ñƒ,Ð¸ EGFR Ð³ÐµÐ½Ð½Ñ‹Ðµ Ð¿Ð¾Ð´Ñ…Ð¾Ð´Ñ‹ Ð²	0.6	0

#	Article	IF	Citations
532	Mitochondrial Metabolism in Melanoma. Cells, 2021, 10, 3197.	1.8	11
533	RAF1 amplification: an exemplar of MAPK pathway activation in urothelial carcinoma. Journal of Clinical Investigation, 2021, 131, .	3.9	6
534	Recent Trends in Rationally Designed Molecules as Kinase Inhibitors. Current Medicinal Chemistry, 2023, 30, 1529-1567.	1.2	4
535	EGFR Pathway-Based Gene Signatures of Druggable Gene Mutations in Melanoma, Breast, Lung, and Thyroid Cancers. Biochemistry (Moscow), 2021, 86, 1477-1488.	0.7	1
536	Unexpected cause of vemurafenib-induced nephrotoxicity: ferrochelatase. Kidney International, 2021, 100, 1158-1160.	2.6	1
537	The role of a new ALK isoform in the diagnosis and targeted therapy of skin melanoma. , 2021, 20, 33-41.	0.3	1
538	The mechanism of Raf activation through dimerization. Chemical Science, 2021, 12, 15609-15619.	3.7	15
539	Potential of Withaferin-A, Withanone and Caffeic Acid Phenethyl ester as ATP-competitive inhibitors of BRAF: A bioinformatics study. Current Research in Structural Biology, 2021, 3, 301-311.	1.1	6
540	Co-targeting MCL-1 and ERK1/2 kinase induces mitochondrial apoptosis in rhabdomyosarcoma cells. Translational Oncology, 2022, 16, 101313.	1.7	6
541	Tracking mutation and drug-driven alterations of oncokinase conformations. Memo - Magazine of European Medical Oncology, 2022, 15, 137-142.	0.3	2
542	A Comprehensive In Silico Exploration of Pharmacological Properties, Bioactivities, Molecular Docking, and Anticancer Potential of Vieloplain F from Xylopia vielana Targeting B-Raf Kinase. Molecules, 2022, 27, 917.	1.7	40
543	Novel Mechanism by a Bis-Pyridinium Fullerene Derivative to Induce Apoptosis by Enhancing the MEK-ERK Pathway in a Reactive Oxygen Species-Independent Manner in BCR-ABL-Positive Chronic Myeloid Leukemia-Derived K562 Cells. International Journal of Molecular Sciences, 2022, 23, 749.	1.8	4
544	Discovery of spiro amide SHR902275: A potent, selective, and efficacious RAF inhibitor targeting RAS mutant cancers. European Journal of Medicinal Chemistry, 2022, 228, 114040.	2.6	5
545	Introduction to cancer biology. , 2022, , 1-17.		0
546	How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC). Cancer Treatment Reviews, 2022, 103, 102335.	3.4	19
547	Structural optimization of 4-(imidazol-5-yl)pyridine derivatives affords broad-spectrum anticancer agents with selective B-RAFV600E/p38Î± kinase inhibitory activity: Synthesis, in vitro assays and in silico study. European Journal of Pharmaceutical Sciences, 2022, 171, 106115.	1.9	4
548	Excellent Response to MEK Inhibition in an AGK-BRAF Gene Fusion Driven Carcinoma: Case Report and Literature Review. Anticancer Research, 2022, 42, 373-379.	0.5	4
550	Association of RAS/BRAF Status and Prognosis of Metastatic Colorectal Cancer: Analysis of 1002 Consecutive Cases. Annals of Surgical Oncology, 2022, 29, 3593-3603.	0.7	3

#	Article	IF	Citations
551	Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes and Diseases, 2023, 10, 1367-1401.	1.5	152
552	Intermittent treatment of BRAF ^{V600E} melanoma cells delays resistance by adaptive resensitization to drug rechallenge. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2113535119.	3.3	20
553	SWI/SNF Chromatin Remodeling Enzymes in Melanoma. Epigenomes, 2022, 6, 10.	0.8	6
554	Heterocyclic Compounds: Importance in Anticancer Drug Discovery. Anti-Cancer Agents in Medicinal Chemistry, 2022, 22, 3196-3207.	0.9	7
555	Allostery: Allosteric Cancer Drivers and Innovative Allosteric Drugs. Journal of Molecular Biology, 2022, 434, 167569.	2.0	26
556	Recent Developments in Targeting RAS Downstream Effectors for RAS-Driven Cancer Therapy. Molecules, 2021, 26, 7561.	1.7	3
557	Structure-Based and Knowledge-Informed Design of B-Raf Inhibitors Devoid of Deleterious PXR Binding. Journal of Medicinal Chemistry, 2022, 65, 1552-1566.	2.9	5
562	Engineered Cas12a-Plus nuclease enables gene editing with enhanced activity and specificity. BMC Biology, 2022, 20, 91.	1.7	15
564	Diagnostic and therapeutic biomarkers in colorectal cancer: a review.. American Journal of Cancer Research, 2022, 12, 661-680.	1.4	0
565	Nephrotoxicity in cancer treatment: An update. Advances in Cancer Research, 2022, , 77-129.	1.9	4
566	Clinical management of metastatic colorectal cancer in the era of precision medicine. Ca-A Cancer Journal for Clinicians, 2022, 72, 372-401.	157.7	167
567	A critical ETV4/Twist1/Vimentin axis in Ha-RAS-induced aggressive breast cancer. Cancer Gene Therapy, 2022, 29, 1590-1599.	2.2	2
569	E3 ligases and deubiquitinating enzymes regulating the MAPK signaling pathway in cancers. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188736.	3.3	36
570	Development of a potent smallâ€molecule degrader against oncogenic <scp>BRAF^{V600E}</scp> protein that evades paradoxical <scp>MAPK</scp> activation. Cancer Science, 2022, 113, 2828-2838.	1.7	5
571	Recent advances in the therapeutic development of ERK inhibitors. , 2022, , 129-178.		0
573	Genetic determinants of lung cancer: Understanding the oncogenic potential of somatic missense mutations. Genomics, 2022, , 110401.	1.3	6
574	Changes in the Transcriptome and Chromatin Landscape in BRAFi-Resistant Melanoma Cells. Frontiers in Oncology, 0, 12, .	1.3	3
575	C2-functionalized imidazo[1,2-a]pyridine: Synthesis and medicinal relevance. Synthetic Communications, 2022, 52, 1337-1356.	1.1	4

#	Article	IF	Citations
576	ANKFN1 plays both protumorigenic and metastatic roles in hepatocellular carcinoma. Oncogene, 0, , .	2.6	0
577	A special subtype: Revealing the potential intervention and great value of KRAS wildtype pancreatic cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188751.	3.3	1
578	Mislocalization of protein kinase A drives pathology in Cushingâ€™s syndrome. Cell Reports, 2022, 40, 111073.	2.9	18
579	ERK5 Signalling and Resistance to ERK1/2 Pathway Therapeutics: The Path Less Travelled?. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	9
581	Efficacy and safety of multi-kinase inhibitors in patients with radioiodine-refractory differentiated thyroid cancer: a systematic review and meta-analysis of clinical trials. Expert Review of Anticancer Therapy, 2022, 22, 999-1008.	1.1	3
582	The overview of Mitogen-activated extracellular signal-regulated kinase (MEK)-based dual inhibitor in the treatment of cancers. Bioorganic and Medicinal Chemistry, 2022, 70, 116922.	1.4	3
583	Discovery of BRAF/HDAC Dual Inhibitors Suppressing Proliferation of Human Colorectal Cancer Cells. Frontiers in Chemistry, 0, 10, .	1.8	3
584	The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer. International Journal of Molecular Sciences, 2022, 23, 8535.	1.8	9
585	In silico high throughput screening and in vitro validation of a novel Raf/Mek dual inhibitor against colorectal carcinoma. , 0, , .		0
586	Diseases of the Canine Prostate Gland. Veterinary Medicine and Science, 0, , .	0.0	1
587	Recurrent tumors of ameloblastoma: Clinicopathologic features and diagnostic outcome. Nigerian Journal of Clinical Practice, 2022, 25, 1771.	0.2	4
588	Computational analysis of natural product B-Raf inhibitors. Journal of Molecular Graphics and Modelling, 2023, 118, 108340.	1.3	2
590	Embracing Project Optimus: Can we Leverage Evolutionary Theory to Optimize Dosing in Oncology?. Pharmaceutical Research, 2022, 39, 3259-3265.	1.7	2
591	RSK2 promotes melanoma cell proliferation and vemurafenib resistance via upregulating cyclin D1. Frontiers in Pharmacology, 0, 13, .	1.6	2
592	Current therapeutic options for glioblastoma and future perspectives. Expert Opinion on Pharmacotherapy, 2022, 23, 1629-1640.	0.9	5
593	RNA-seq and ChIP-seq Identification of Unique and Overlapping Targets of GLI Transcription Factors in Melanoma Cell Lines. Cancers, 2022, 14, 4540.	1.7	3
594	Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis. Cancer Research, 2022, 82, 4261-4273.	0.4	8
595	Harnessing TRAIL-induced cell death for cancer therapy: a long walk with thrilling discoveries. Cell Death and Differentiation, 2023, 30, 237-249.	5.0	23

#	Article	IF	Citations
596	Identification of novel natural drug candidates against BRAF mutated carcinoma; An integrative in-silico structure-based pharmacophore modeling and virtual screening process. Frontiers in Chemistry, 0, 10, .	1.8	5
597	Escape from G1 arrest during acute MEK inhibition drives the acquisition of drug resistance. NAR Cancer, 2022, 4, .	1.6	1
598	ERK1/2 in immune signalling. Biochemical Society Transactions, 2022, 50, 1341-1352.	1.6	29
600	Clinical associations and genetic interactions of oncogenic BRAF alleles. PeerJ, 0, 10, e14126.	0.9	0
603	Some things old, new and borrowed: Delivery of dabrafenib and vemurafenib to melanoma cells via self-assembled nanomicelles based on an amphiphilic dendrimer. European Journal of Pharmaceutical Sciences, 2023, 180, 106311.	1.9	2
604	CRISPR/Cas9 Edited RAS & MEK Mutant Cells Acquire BRAF and MEK Inhibitor Resistance with MEK1 Q56P Restoring Sensitivity to MEK/BRAF Inhibitor Combo and KRAS G13D Gaining Sensitivity to Immunotherapy. Cancers, 2022, 14, 5449.	1.7	4
605	RASopathy mutations open new insights into the mechanism of BRAF activation. Molecular Cell, 2022, 82, 4192-4193.	4.5	2
606	<scp>MEK1</scp>â€dependent <scp>MondoA</scp> phosphorylation regulates glucose uptake in response to ketone bodies in colorectal cancer cells. Cancer Science, 2023, 114, 961-975.	1.7	2
607	Dieckol Inhibits Autophagic Flux and Induces Apoptotic Cell Death in A375 Human Melanoma Cells via Lysosomal Dysfunction and Mitochondrial Membrane Impairment. International Journal of Molecular Sciences, 2022, 23, 14149.	1.8	8
608	Future Role of Molecular Profiling in Small Breast Samples and Personalised Medicine. , 2022, , 895-915.		0
609	Insights into the aberrant CDK4/6 signaling pathway as a therapeutic target in tumorigenesis. Advances in Protein Chemistry and Structural Biology, 2023, , 179-201.	1.0	4
610	Glucocorticoid receptor and RAS: an unexpected couple in cancer. Trends in Cell Biology, 2022, , .	3.6	2
611	Histology-Agnostic Drugs: A Paradigm Shiftâ€”A Narrative Review. Advances in Therapy, 2023, 40, 1379-1392.	1.3	3
612	Inhibition of mutant RAS-RAF interaction by mimicking structural and dynamic properties of phosphorylated RAS. ELife, 0, 11, .	2.8	4
613	3-Bromopyruvate Suppresses the Malignant Phenotype of Vemurafenib-Resistant Melanoma Cells. International Journal of Molecular Sciences, 2022, 23, 15650.	1.8	4
614	Kinase Inhibitors in the Treatment of Ovarian Cancer: Current State and Future Promises. Cancers, 2022, 14, 6257.	1.7	5
615	Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy. Molecular Biomedicine, 2022, 3, .	1.7	29
616	A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study. BMC Cancer, 2022, 22, .	1.1	3

#	Article	IF	Citations
617	MAPK inhibitors dynamically affect melanoma release of immune NKG2D-ligands, as soluble protein and extracellular vesicle-associated. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	2
618	Response and resistance to BRAFV600E inhibition in gliomas: Roadblocks ahead?. Frontiers in Oncology, 0, 12, .	1.3	3
619	The adaptor protein VEPH1 interacts with the kinase domain of ERBB2 and impacts EGF signaling in ovarian cancer cells. Cellular Signalling, 2023, 106, 110634.	1.7	0
620	New approaches to targeted therapy for metastatic melanoma in the presence of rare genetic changes in the tumor. Onkologiya Zhurnal Imeni P A Gertsena, 2023, 12, 65.	0.0	0
621	PIP5K1C phosphoinositide kinase deficiency distinguishes PIKFYVE-dependent cancer cells from non-malignant cells. Autophagy, 2023, 19, 2464-2484.	4.3	2
622	State of the Art: ctDNA in Upper Gastrointestinal Malignancies. Cancers, 2023, 15, 1379.	1.7	3
623	Design, synthesis and characterisation of a novel type II B-RAF paradox breaker inhibitor. European Journal of Medicinal Chemistry, 2023, 250, 115231.	2.6	1
624	GRM2 Regulates Functional Integration of Adult-Born DGCs by Paradoxically Modulating MEK/ERK1/2 Pathway. Journal of Neuroscience, 2023, 43, 2822-2836.	1.7	1
625	Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond. World Journal of Gastroenterology, 0, 29, 1395-1426.	1.4	8
626	Functional precision oncology using patient-derived assays: bridging genotype and phenotype. Nature Reviews Clinical Oncology, 2023, 20, 305-317.	12.5	18
627	Targeted therapies in advanced biliary tract cancersâ€"a narrative review. Chinese Clinical Oncology, 2023, 12, 14-14.	0.4	5
628	Multi-range ERK responses shape the proliferative trajectory of single cells following oncogene induction. Cell Reports, 2023, 42, 112252.	2.9	5
629	Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib. Journal of Biological Chemistry, 2023, 299, 104634.	1.6	8
630	ERK1/2 inhibitors act as monovalent degraders inducing ubiquitylation and proteasome-dependent turnover of ERK2, but not ERK1. Biochemical Journal, 0, , .	1.7	2
648	An updated literature on BRAF inhibitors (2018â€"2023). Molecular Diversity, 0, , .	2.1	1
651	2-Aminopyrimidine. , 2023, , 391-404.		0
652	The mechanism and consequences of BRAF inhibitor resistance in melanoma. Genome Instability & Disease, 2023, 4, 266-274.	0.5	3
657	Navigating the Endoplasmic Reticulum: New Insights and Emerging Concepts. Biochemistry, 0, , .	0.8	0

#	Article	IF	Citations
667	Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	7
677	Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma. American Journal of Clinical Dermatology, 0, , .	3.3	0